Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q4 2021
Holdings as of Dec 31, 2021, filed Feb 14, 2022. Long positions only; changes compare share counts with Q3 2021.
- Positions
- 35
- 0 vs. Q3 2021
- Portfolio value
- $447.4M
- +$24.5M (+5.8%) vs. Q3 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ARNAArena Pharmaceuticals Inc | COM NEW | 530,670 | $49.3M | 11.0% | 00.0% | Unchanged | History |
| EXELExelixis, Inc. | COM | 1,750,000 | $32.0M | 7.2% | +225,000+14.8% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 950,000 | $29.7M | 6.6% | +250,000+35.7% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 800,000 | $24.8M | 5.6% | +175,000+28.0% | Added | History |
| ANABAnaptysbio, Inc | COM | 592,250 | $20.6M | 4.6% | +42,705+7.8% | Added | History |
| VRTXVertex Pharmaceuticals Inc | Stock | 85,000 | $18.7M | 4.2% | 00.0% | Unchanged | History |
| BCABBioAtla, Inc. | COM | 864,300 | $17.0M | 3.8% | +20,298+2.4% | Added | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 300,000 | $16.5M | 3.7% | +300,000 | New | History |
| RLMDRelmada Therapeutics, Inc. | COM | 717,320 | $16.2M | 3.6% | +717,320 | New | History |
| MGNXMacrogenics Inc | COM | 1,000,000 | $16.1M | 3.6% | 00.0% | Unchanged | History |
| CYTKCytokinetics Inc | COM NEW | 350,000 | $16.0M | 3.6% | −41,429−10.6% | Reduced | History |
| TCDATricida, Inc. | COM | 1,400,000 | $13.4M | 3.0% | −574,000−29.1% | Reduced | History |
| RIGLRigel Pharmaceuticals Inc | COM NEW | 5,000,000 | $13.3M | 3.0% | +3,020,000+152.5% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 145,405 | $13.1M | 2.9% | +145,405 | New | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 200,000 | $12.2M | 2.7% | +200,000 | New | History |
| PCVXVaxcyte, Inc. | COM | 500,000 | $11.9M | 2.7% | +401,939+409.9% | Added | History |
| Avidity Biosciences, Inc.05370A108 | COM | 500,000 | $11.9M | 2.7% | +500,000 | New | – |
| ACRSAclaris Therapeutics, Inc. | COM | 800,000 | $11.6M | 2.6% | +300,000+60.0% | Added | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 500,526 | $10.9M | 2.4% | −264,474−34.6% | Reduced | History |
| SLNSilence Therapeutics plc | ADS | 444,443 | $10.6M | 2.4% | +444,443 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 845,000 | $10.0M | 2.2% | +100,000+13.4% | Added | History |
| PASGPassage BIO, Inc. | COM | 1,518,095 | $9.64M | 2.2% | +1,518,095 | New | History |
| PRQRProQR Therapeutics N.V. | SHS EURO | 1,121,122 | $8.98M | 2.0% | +1,090,786+3,595.7% | Added | History |
| URGNUroGen Pharma Ltd. | COM | 873,424 | $8.31M | 1.9% | +123,424+16.5% | Added | History |
| KDNYChinook Therapeutics, Inc. | COM | 390,041 | $6.36M | 1.4% | +390,041 | New | History |
| KNSAKiniksa Pharmaceuticals International, plc | COM CL A | 536,738 | $6.32M | 1.4% | +56,738+11.8% | Added | History |
| Pieris Pharmaceuticals Inc720795103 | COM | 1,550,000 | $5.86M | 1.3% | +1,550,000 | New | – |
| KALVKalVista Pharmaceuticals, Inc. | COM | 411,937 | $5.45M | 1.2% | +411,937 | New | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,170,000 | $5.18M | 1.2% | 00.0% | Unchanged | History |
| PYXSPyxis Oncology, Inc. | COMMON STOCK | 400,000 | $4.39M | 1.0% | +400,000 | New | History |
| SYRESpyre Therapeutics, Inc. | COM | 910,251 | $4.32M | 1.0% | +10,251+1.1% | Added | History |
| ABUSArbutus Biopharma Corp | COM | 668,907 | $2.60M | 0.6% | +668,907 | New | History |
| CABACabaletta Bio, Inc. | COM | 472,433 | $1.79M | 0.4% | +472,433 | New | History |
| RFLRafael Holdings, Inc. | COM CL B | 285,714 | $1.46M | 0.3% | 00.0% | Unchanged | History |
| PNTPOINT Biopharma Global Inc. | COM | 190,520 | $1.07M | 0.2% | +190,520 | New | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| NKTRNektar Therapeutics | COM | – | $2.75M |
Sold out since Q3 2021 (14)
Positions held at the end of Q3 2021 that are gone from this filing.
| Security | Class | Shares in Q3 2021 | Value in Q3 2021 | % of portfolio in Q3 2021 | History |
|---|---|---|---|---|---|
| KDMNKadmon Holdings, Inc. | COM | 3,375,000 | $29.4M | 7.0% | History |
| DRNADicerna Pharmaceuticals Inc | COM | 799,999 | $16.1M | 3.8% | History |
| UTHRUnited Therapeutics Corp | COM | 86,667 | $16.0M | 3.8% | History |
| BIIBBiogen Inc. | COM | 47,500 | $13.4M | 3.2% | History |
| SAGESage Therapeutics, Inc. | COM | 269,010 | $11.9M | 2.8% | History |
| PBYIPuma Biotechnology, Inc. | COM | 1,300,000 | $9.11M | 2.2% | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 329,086 | $9.07M | 2.1% | History |
| NKTRNektar Therapeutics | COM | 504,691 | $9.06M | 2.1% | History |
| CTMXCytomX Therapeutics, Inc. | COM | 1,500,000 | $7.63M | 1.8% | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 220,863 | $7.09M | 1.7% | History |
| RPTXRepare Therapeutics Inc. | COM | 93,137 | $2.44M | 0.6% | History |
| COLLCollegium Pharmaceutical, Inc | COM | 121,342 | $2.40M | 0.6% | History |
| FOLDAmicus Therapeutics, Inc. | COM | 249,000 | $2.38M | 0.6% | History |
| IFRXInflaRx N.V. | COM | 551,918 | $1.43M | 0.3% | History |